tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Eric Schmidt, 32 are a BUY (100%).
Analyst Eric Schmidt, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 53.61% that have a potential upside of 23.43% achieved within 691 days.
Eric Schmidt’s has documented 62 price targets and ratings displayed on 19 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on RNA, Avidity Biosciences at 27-Jun-2025.
Analyst best performing recommendations are on BIIB (BIOGEN).
The best stock recommendation documented was for BIIB (BIOGEN) at 1/2/2018. The price target of $338 was fulfilled within 1 day with a profit of $3.83 (1.15%) receiving and performance score of 11.46.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$210
$55.73 (36.12%)
$213
3 days ago
(31-Oct-2025)
39/70 (55.71%)
$55.73 (36.12%)
121
Hold
$149
$-5.27 (-3.42%)
$152
24 days ago
(10-Oct-2025)
24/47 (51.06%)
$2.43 (1.66%)
266
Hold
1 months 10 days ago
(24-Sep-2025)
7/32 (21.88%)
$112.06 (70.95%)
255
Hold
$118
$-36.27 (-23.51%)
$115
2 months 20 days ago
(14-Aug-2025)
0/2 (0%)
$-16.94 (-12.55%)
Buy
$187
$32.73 (21.22%)
$187
4 months 8 days ago
(26-Jun-2025)
9/23 (39.13%)
$60.08 (47.34%)
260
Which stock is Eric Schmidt is most bullish on?
What Year was the first public recommendation made by Eric Schmidt?
